sharesgurusharesguru
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
LoginSign Up
sharesguru
  • Home
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
  • Profile
  • Contact Us
LoginSign Up
sharesguru

Discover the joy of investing.

All the financial data and tools you need, at one place.

Navigation

  • Home
  • Stocks
  • Sectors

Tools

  • Ai Screener
  • Watchlists

Company

  • Contact

Legal

  • Privacy Policy
  • Terms of Service
Copyright © 2025 Knowtilus Technologies Pvt. Ltd.
SummaryLatest NewsSector ComparisonEarnings ReportRevenue & GrowthPeersIncome StatementBalance SheetCash Flow
KIMS logo

KIMS - Krishna Institute of Medical Sciences Limited Share Price

Healthcare Services
Sharesguru Stock Score

KIMS

55/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹764.10-5.05(-0.66%)
Market Closed as of May 22, 2026, 15:30 IST
Pros

Size: Market Cap wise it is among the top 20% companies of india.

Growth: Awesome revenue growth! Revenue grew 28.2% over last year and 76.8% in last three years on TTM basis.

Past Returns: Outperforming stock! In past three years, the stock has provided 34.3% return compared to 8.9% by NIFTY 50.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money has been increasing their position in the stock.

Balance Sheet: Reasonably good balance sheet.

Cons

Dividend: Stock hasn't been paying any dividend.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Sharesguru Stock Score

KIMS

55/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Valuation

Market Cap30.85 kCr
Price/Earnings (Trailing)128.07
Price/Sales (Trailing)7.85
EV/EBITDA41.66
Price/Free Cashflow-33.64
MarketCap/EBT93.12
Enterprise Value34.04 kCr

Fundamentals

Revenue (TTM)3.93 kCr
Rev. Growth (Yr)35.3%
Earnings (TTM)242 Cr
Earnings Growth (Yr)-68.8%

Profitability

Operating Margin9%
EBT Margin8%
Return on Equity9.46%
Return on Assets3.12%
Free Cashflow Yield-2.97%

Growth & Returns

Price Change 1W-0.30%
Price Change 1M13.2%
Price Change 6M15.1%
Price Change 1Y16.3%
3Y Cumulative Return34.3%

Cash Flow & Liquidity

Cash Flow from Investing (TTM)-1.45 kCr
Cash Flow from Operations (TTM)510.8 Cr
Cash Flow from Financing (TTM)940.3 Cr
Cash & Equivalents55.4 Cr
Free Cash Flow (TTM)-917.1 Cr
Free Cash Flow/Share (TTM)-22.92

Balance Sheet

Total Assets7.76 kCr
Total Liabilities5.2 kCr
Shareholder Equity2.56 kCr
Current Assets937.4 Cr
Current Liabilities1.24 kCr
Net PPE4.19 kCr
Inventory96.9 Cr
Goodwill338.6 Cr

Capital Structure & Leverage

Debt Ratio0.42
Debt/Equity1.27
Interest Coverage0.64
Interest/Cashflow Ops3.52

Dividend & Shareholder Returns

Shares Dilution (1Y)0.00%
Shares Dilution (3Y)0.00%
Pros

Size: Market Cap wise it is among the top 20% companies of india.

Growth: Awesome revenue growth! Revenue grew 28.2% over last year and 76.8% in last three years on TTM basis.

Past Returns: Outperforming stock! In past three years, the stock has provided 34.3% return compared to 8.9% by NIFTY 50.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money has been increasing their position in the stock.

Balance Sheet: Reasonably good balance sheet.

Cons

Dividend: Stock hasn't been paying any dividend.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Shares Dilution (1Y)0.00%
Earnings/Share (TTM)6.02

Financial Health

Current Ratio0.76
Debt/Equity1.27

Technical Indicators

RSI (14d)67.87
RSI (5d)48.96
RSI (21d)62.37
MACD SignalBuy
Stochastic Oscillator SignalHold
SharesGuru SignalBuy
RSI SignalHold
RSI5 SignalHold
RSI21 SignalHold
SMA 5 SignalBuy
SMA 10 SignalBuy
SMA 20 SignalBuy
SMA 50 SignalBuy
SMA 100 SignalBuy

Summary of Latest Earnings Report from Krishna Institute of Medical Sciences

Summary of Krishna Institute of Medical Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

In the Q3 FY26 earnings conference call for KIMS Hospitals, management provided an optimistic outlook while addressing operational and financial developments. Dr. Bhaskar Rao Bollineni highlighted a record-breaking quarter, with total revenue surpassing INR 1,000 crores at INR 1,003 crores, showing a year-on-year increase of 2.2% and a quarter-on-quarter growth of 3.9%. EBITDA was reported at INR 204 crores, reflecting a marginal decline due to new unit costs, resulting in an EBITDA margin of 20.4%.

Management emphasized the ongoing stabilization of new units, forecasting that break-even for Thane and Mahadevapura will occur in Q1 FY27, while Electronic City is projected to reach break-even by Q3 FY27. They expressed confidence in average revenue per operating bed (ARPOB), projecting it to normalize around INR 70,000 - 75,000 in Karnataka. The audience was informed that cash and cash equivalents stood at INR 206 crores as of December 31, 2025.

Dr. Abhinay Bollineni also discussed the future expansion strategy, indicating a new hospital in Chennai and exploring further opportunities in Tamil Nadu. They anticipate a capex of INR 500-600 crores for FY27, without additional debt increase, as existing expansions reach completion. Management stressed the continuous onboarding of doctors and potential growth in specialties would drive revenue increases.

Overall, KIMS Hospitals is focused on optimizing existing facilities, maintaining a healthy debt outlook, and strategically expanding in underserved markets.

Here are the major questions and their detailed answers from the Q&A section of the earnings transcript:

  1. Question: "Is it possible for the management to provide the occupancy number for Thane as well as two Bangalore assets and also the trajectory for the EBITDA losses for these three units in the coming quarters, especially for quarter 4 and FY '26?"
    Answer: "It may be difficult to provide specific occupancy details as all three assets are still growing. However, we expect to achieve EBITDA positive or neutral status for Thane and Mahadevapuram by the end of Q1 next financial year. Electronic City may take a bit longer due to its later commissioning in December, but we anticipate it will also turn EBITDA neutral by the end of Q3."

  2. Question: "Should we consider some normalization in these ARPOBs because this is just the first few quarters of the hospitals getting started or do you think these ARPOBs are maintainable going ahead?"
    Answer: "You should probably discount the numbers a bit, considering we have done a significant amount of transplant work lately. While we have seen ARPOBs over INR76,000, these should stabilize around INR70,000-75,000, similar to the Telangana cluster."

  3. Question: "Is there anything to read into volume growth in Andhra and Telangana clusters, and do you expect performance to improve?"
    Answer: "The volume growth in Telangana has shown a healthy 20% year-on-year. Andhra's dip in Q3 was due to a state government strike impacting the Aarogyasri scheme. January shows improvement in revenues, indicating recovery."

  4. Question: "Can you update the status on NABH accreditation for Nashik and Thane units and the progress on insurance empanelments?"
    Answer: "The entry level for NABH in Nashik is complete, and Thane's is in the pipeline. NABH is not a prerequisite for insurance empanelment; some progress has been made with the top five insurers, with two contracts closed and the remaining three expected by quarter's end."

  5. Question: "Given the rise in ARPOB and ARPP, is transplant the only moving factor, or have other variables changed?"
    Answer: "Both factors have contributed. The high ARPOB markets of Thane and Bangalore, combined with outpatient services and the recent addition of onco services, have increased revenue. However, future growth may need careful management due to varying state performances."

  6. Question: "What are your expectations for the Telangana cluster in terms of optimal occupancy in future?"
    Answer: "We aim for an occupancy of 75%-80% in Telangana. Some beds are currently closed for renovations, but this should improve with the commissioning of new beds by the end of next year, thus boosting volume growth."

  7. Question: "What's the net debt position as of December 31?"
    Answer: "Our consolidated net debt stands at approximately INR2,850 crores as of December 31, 2025."

  8. Question: "How many of the top five insurers have been empaneled for Kerala and what's the timeline for Bangalore?"
    Answer: "In Kerala, empanelment in Kannur is complete, while Kollam is still progressing. For Bangalore, we anticipate it may take an additional 6-9 months to complete this process."

  9. Question: "Can you share updates on the upcoming hospitals in Andhra Pradesh?"
    Answer: "Onngol's 50-bed expansion is complete, and Anantapur is expected by the end of March. Our new hospitals in Rajahmundry, Kundapur, and Kompali will also begin commissioning soon."

  10. Question: "What are your plans regarding expansion in Chennai and further in Tamil Nadu?"
    Answer: "We've identified underserved micro-markets in Chennai and plan to expand there, potentially considering other Tamil Nadu cities in the future, but currently focusing on Chennai."

Each answer summarizes the key points discussed during the conference call while adhering to the constraints regarding character limits and specifics.

Share Holdings

Understand Krishna Institute of Medical Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

Shareholder NameHolding %
Bhaskara Rao Bollineni26.27%
Bluebridge Capital Private Limited6.05%
Sbi Small Cap Fund5.89%
Hdfc Small Cap Fund4.35%
Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund4.33%
Bollineni Seenaiah Naidu4.12%
Invesco India Flexi Cap Fund3.55%
Amansa Holdings Private Limited2.34%
Lilac Investments Limited1.96%
Sbi Life Insurance Co. Ltd1.92%
Rajyasri Bollineni1.72%
Nomura India Investment Fund Mother Fund1.59%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 1101.44%
Venkata Krishna Kumar Kodali1.26%
Abhinay Bollineni0.06%
Sweata Raavi0.01%
Adwik Bollineni0.01%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Krishna Institute of Medical Sciences Better than it's peers?

Detailed comparison of Krishna Institute of Medical Sciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr
APOLLOHOSPApollo Hospitals Enterprises1.2 LCr25.42 kCr+7.50%+19.20%61.634.71--
FORTISFortis Healthcare73.31 kCr8.84 kCr+5.90%+44.50%76.348.3--
NHNarayana Hrudayalaya39.36 kCr6.88 kCr+6.80%+10.60%50.225.72--
MEDANTAGlobal Health33.33 kCr4.51 kCr+14.70%+4.80%59.877.39--
HCGHealthCare Global Enterprises9.36 kCr2.57 kCr+9.10%+3.40%646.393.64--

Sector Comparison: KIMS vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

KIMS metrics compared to Healthcare

CategoryKIMSHealthcare
PE128.07 64.84
PS7.856.58
Growth28.2 %16.1 %
67% metrics above sector average
Key Insights
  • 1. KIMS is among the Top 10 Hospital companies but not in Top 5.
  • 2. The company holds a market share of 5.2% in Hospital.
  • 3. In last one year, the company has had an above average growth that other Hospital companies.

Income Statement for Krishna Institute of Medical Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Revenue From Operations28.7%3,9053,0352,4982,1981,6511,330
Other Income-19.4%263213262010
Total Income28.2%3,9313,0672,5112,2241,6711,340
Cost of Materials-00000283
Purchases of stock-in-trade31.6%8426405374743680
Employee Expense36.5%682500422346262220
Finance costs125.8%2029047311632
Depreciation and Amortization60.2%2831771471297370
Other expenses43.2%1,6121,126905767518450
Total Expenses42.4%3,5882,5202,0511,7531,2241,061
Profit Before exceptional items and Tax-37.5%342547460470447279
Exceptional items before tax-222%-11.21101500
Total profit before tax-40.8%331558460485447279
Current tax-9.4%13615012011711478
Deferred tax-529.2%-44.3-6.24.032.480.17-4.3
Total tax-35.9%9214312411911474
Total profit (loss) for period-41.8%242415336366344205
Other comp. income net of taxes75.8%0.2-2.30.330.850.12-0.46
Total Comprehensive Income-41.4%242412336367344205
Earnings Per Share, Basic-41.6%6.039.617.758.4068.3765.374
Earnings Per Share, Diluted-41.6%6.039.617.758.4068.3765.24
Description(%) Q/QMar-2026Dec-2025Sep-2025Jun-2025Mar-2025Dec-2024
Revenue From Operations7.7%1,075998961872797772
Other Income107.1%9.75.24.27.14.518
Total Income8.1%1,0841,003965879801790
Purchases of stock-in-trade11.4%235211204192169170
Employee Expense2.3%180176174151134128
Finance costs19.6%685745332726
Depreciation and Amortization7.7%857966535345
Other expenses6.8%455426387344298296
Total Expenses9.3%1,021934868765678656
Profit Before exceptional items and Tax-8.8%636997114123135
Exceptional items before tax--10.90-0.30110
Total profit before tax-25%526997114134135
Current tax6.2%353338323635
Deferred tax19%-13.1-16.4-12.9-3.7-7.86.8
Total tax31.2%221725292842
Total profit (loss) for period-37.3%3352728510692
Other comp. income net of taxes-0.400.3-0.50.8-0.9
Total Comprehensive Income-35.3%3452728410792
Earnings Per Share, Basic-81.8%1.061.331.671.962.542.22
Earnings Per Share, Diluted-81.8%1.061.331.671.962.542.22
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Revenue From Operations23%1,7021,3841,2221,1321,143933
Other Income0%57571624249.62
Total Income22%1,7581,4411,2381,1561,168942
Cost of Materials-00000196
Purchases of stock-in-trade24%3472802542312590
Employee Expense23.4%291236220187174147
Finance costs254.5%79233.661.154.4715
Depreciation and Amortization49.1%865858454545
Other expenses33.8%610456387347323280
Total Expenses33.4%1,3981,048919818797688
Profit Before exceptional items and Tax-8.2%360392318337371254
Exceptional items before tax-180%-7110000
Total profit before tax-12.4%353403318337371254
Current tax-22.3%749583849167
Deferred tax314.6%185.1-0.641.081.71-1.2
Total tax-8.1%9210083859366
Total profit (loss) for period-13.9%261303235252278189
Other comp. income net of taxes56.5%0-1.30.250.820.2-0.48
Total Comprehensive Income-13.6%261302236253279188
Earnings Per Share, Basic-16%6.527.575.8826.31785.04
Earnings Per Share, Diluted-16%6.527.575.8826.31784.954
Description(%) Q/QMar-2026Dec-2025Sep-2025Jun-2025Mar-2025Dec-2024
Revenue From Operations3.2%456442430373346348
Other Income30.8%181412122421
Total Income4%474456442386370368
Purchases of stock-in-trade5.9%918692787175
Employee Expense-2.7%727476685857
Finance costs23.8%272218128.16.7
Depreciation and Amortization13.6%262320181515
Other expenses3.2%163158156132108118
Total Expenses5.6%378358356306260266
Profit Before exceptional items and Tax-2.1%96988680110102
Exceptional items before tax--6.70-0.30110
Total profit before tax-9.3%89988680121102
Current tax-10.5%182019172024
Deferred tax-2.4%55.13.93.56.61.8
Total tax-8.3%232523212725
Total profit (loss) for period-8.5%667264599476
Other comp. income net of taxes-0.100.2-0.30.8-0.7
Total Comprehensive Income-8.5%667264589476
Earnings Per Share, Basic-19.8%1.651.811.591.472.341.91
Earnings Per Share, Diluted-19.8%1.651.811.591.472.341.91

Balance Sheet for Krishna Institute of Medical Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Sep-2025Mar-2025Sep-2024Mar-2024Sep-2023
Cash and cash equivalents-32.5%558156634738
Current investments-26.3%152022138366
Loans, current144.8%723048000
Total current financial assets13.8%784689596529462440
Inventories21.5%978064544950
Current tax assets-101.8%056004635
Total current assets6.6%937879697625593560
Property, plant and equipment19.5%4,1863,5022,1991,8471,7301,233
Capital work-in-progress5.8%6065731,214854600638
Goodwill0%339339339379308308
Non-current investments-100.5%0.6780.60.67450
Loans, non-current87.5%137.45.565260
Total non-current financial assets602.7%1,3081876614719388
Total non-current assets18.7%6,8215,7465,0393,9543,2592,859
Total assets17.1%7,7596,6255,7364,5793,8523,419
Borrowings, non-current0.1%2,6732,6702,2871,5601,226901
Total non-current financial liabilities39.8%3,8482,7522,3651,5701,233901
Provisions, non-current25%463734332725
Total non-current liabilities36.4%3,9612,9042,4811,6381,306974
Borrowings, current10.5%57151727022212954
Total current financial liabilities8.3%1,1281,042754578387301
Provisions, current23.1%332726201914
Current tax liabilities-115.2%07.61.61206.9
Total current liabilities8.1%1,2391,146836658452360
Total liabilities28.4%5,2004,0493,3172,2961,7591,334
Equity share capital0%808080808080
Non controlling interest1.6%311306281281265271
Total equity-0.7%2,5582,5762,4192,2832,0932,085
Total equity and liabilities17.1%7,7596,6255,7364,5793,8523,419
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Sep-2025Mar-2025Sep-2024Mar-2024Sep-2023
Cash and cash equivalents-17.2%253026182022
Current investments-105.3%020006243
Loans, current338.6%266.774.79.150
Total current financial assets1.1%367363273237279212
Inventories14.7%403526212225
Current tax assets--0003.650
Total current assets9.1%434398299276305257
Property, plant and equipment7.4%1,3981,302724633627601
Capital work-in-progress26.4%1169253035129217
Non-current investments19.8%1,5231,2711,2261,1361,001836
Loans, non-current40.4%62044227620696107
Total non-current financial assets24.4%2,2801,8331,5861,3611,106956
Total non-current assets17.6%3,8513,2742,8902,4702,0921,709
Total assets16.7%4,2853,6713,1892,7472,3961,966
Borrowings, non-current52.6%1,1037235773722570
Total non-current financial liabilities62.9%1,1857285803882670.02
Provisions, non-current19%262221221918
Total non-current liabilities57.1%1,29282366244032162
Borrowings, current6.4%350329131117690
Total current financial liabilities1.2%499493309252165107
Provisions, current21.4%18151411106.87
Current tax liabilities--6.91.61103.48
Total current liabilities1.3%565558359308209144
Total liabilities34.4%1,8561,3811,021749530206
Equity share capital0%808080808080
Total equity6.1%2,4292,2902,1681,9981,8661,760
Total equity and liabilities16.7%4,2853,6713,1892,7472,3961,966

Cash Flow for Krishna Institute of Medical Sciences

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Finance costs14.2%202177473116-
Change in inventories-137.1%-32.9-13.3-6.586.47-12.34-
Depreciation216.9%2839014712973-
Impairment loss / reversal-00-1.4600-
Adjustments for interest income13.3%18162.299.5312-
Net Cashflows from Operations-8.4%662723661530520-
Interest received-000-2.450-
Income taxes paid (refund)7.1%151141140950-
Net Cashflows From Operating Activities-12.2%511582521432520-
Cashflows used in obtaining control of subsidiaries-100.6%0178752160-
Cash payment for investment in partnership firm or association of persons or LLP-8.40000-
Proceeds from sales of PPE-102.2%0471.412.630.32-
Purchase of property, plant and equipment41.6%1,4281,009647526170-
Proceeds from sales of investment property-150000-
Purchase of intangible assets-000490-
Interest received31.6%118.61.61113-
Income taxes paid (refund)-0000127-
Other inflows (outflows) of cash51.2%-10.8-23.2-7.531620-
Net Cashflows From Investing Activities-30%-1,451.7-1,116.2-752.56-615.6-606.48-
Payments from changes in ownership interests in subsidiaries78.2%1568818101.13-
Proceeds from issuing shares-49000192-
Proceeds from borrowings75.3%1,538878531389124-
Repayments of borrowings151.8%2108418241233-
Payments of lease liabilities87.2%744056410-
Dividends paid-2070000-
Interest paid-100.8%0123591912-
Net Cashflows from Financing Activities73.2%9405432178860-
Net change in cash and cash eq.-120.8%-0.68.7-14.72-95.17-26.5-
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2026Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Finance costs254.5%79233.661.154.47-
Change in inventories-178.8%-13.5-4.2-2.876.74-11.59-
Depreciation49.1%8658584545-
Impairment loss / reversal-00-2.6800-
Dividend income-0000.260-
Adjustments for interest income100%51269.451117-
Net Cashflows from Operations-2.9%372383348503436-
Dividends received-0000.260-
Income taxes paid (refund)-11.2%809085750-
Net Cashflows From Operating Activities-0.3%293294262429436-
Cashflows used in obtaining control of subsidiaries37.4%3022202142340-
Proceeds from sales of PPE-98.9%1.5460.530.440.24-
Purchase of property, plant and equipment1.4%35735232112169-
Cash receipts from repayment of advances and loans made to other parties28.1%147115-37.5101142-
Interest received60%25161.81316-
Income taxes paid (refund)-000096-
Other inflows (outflows) of cash50%-1.2-3.41.85-39.520-
Net Cashflows From Investing Activities-52.5%-955.9-626.6-568.65-395.03-527.21-
Proceeds from issuing shares-0000192-
Proceeds from borrowings103.7%82240432600-
Repayments of borrowings271.4%79224.1714110-
Payments of lease liabilities-002900-
Interest paid90.5%81434.51.164.22-
Net Cashflows from Financing Activities95.6%662339289-15.3976-
Net change in cash and cash eq.-143.5%-15.6-17.6218-14.73-

What does Krishna Institute of Medical Sciences Limited do?

Hospital•Healthcare•Small Cap

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, Alzheimer's, bone, joint center specialties, and others. In addition, the company provides medical procedures for aneurysm, ankle arthritis and total ankle replacement, anterior cervical discectomy and fusion surgery, anterior resection, aortic aneurysm, aortic stent graft, aortic valve replacement, arthroscopy, atrial septal defect, bariatric surgery, and others. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Industry Group:Healthcare Services
Employees:5,013
Website:www.kimshospitals.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Performance Comparison

KIMS vs Healthcare (2022 - 2026)

KIMS leads the Healthcare sector while registering a 14.6% growth compared to the previous year.